{ "resourceType" : "ConceptMap", "id" : "mii-cm-onko-atc-transitions-2022", "meta" : { "extension" : [{ "url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license", "valueCode" : "CC-BY-4.0" }, { "extension" : [{ "url" : "packageId", "valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie" }, { "url" : "version", "valueString" : "2027.0.0-ballot.1" }, { "url" : "uri", "valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko" }], "url" : "http://hl7.org/fhir/StructureDefinition/package-source" }], "profile" : ["http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap", "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"] }, "language" : "de", "text" : { "status" : "generated", "div" : "

German

Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2022

Profiles: CRMI Shareable ConceptMap, CRMI Publishable ConceptMap

Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2021 to MII VS Onkologie Systemische Therapie Substanzen ATC 2022


Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)

Source CodeRelationshipTarget CodeComment
L01XC02 (Rituximab)is equivalent toL01FA01 (Rituximab)Reklassifizierung zu CD20-Inhibitoren
L01XC15 (Obinutuzumab)is equivalent toL01FA03 (Obinutuzumab)Reklassifizierung zu CD20-Inhibitoren
L01XC26 (Inotuzumab ozogamicin)is equivalent toL01FB01 (Inotuzumab ozogamicin)Reklassifizierung zu CD22-Inhibitoren
L01XC24 (Daratumumab)is equivalent toL01FC01 (Daratumumab)Reklassifizierung zu CD38-Inhibitoren
L01XC03 (Trastuzumab)is equivalent toL01FD01 (Trastuzumab)Reklassifizierung zu HER2-Inhibitoren
L01XC13 (Pertuzumab)is equivalent toL01FD02 (Pertuzumab)Reklassifizierung zu HER2-Inhibitoren
L01XC14 (Trastuzumab emtansin)is equivalent toL01FD03 (Trastuzumab emtansin)Reklassifizierung zu HER2-Inhibitoren
L01XC06 (Cetuximab)is equivalent toL01FE01 (Cetuximab)Reklassifizierung zu EGFR-Inhibitoren
L01XC08 (Panitumumab)is equivalent toL01FE02 (Panitumumab)Reklassifizierung zu EGFR-Inhibitoren
L01XC17 (Nivolumab)is equivalent toL01FF01 (Nivolumab)Reklassifizierung zu PD-1-/PD-L1-Inhibitoren
L01XC18 (Pembrolizumab)is equivalent toL01FF02 (Pembrolizumab)Reklassifizierung zu PD-1-/PD-L1-Inhibitoren
L01XC28 (Durvalumab)is equivalent toL01FF03 (Durvalumab)Reklassifizierung zu PD-1-/PD-L1-Inhibitoren
L01XC31 (Avelumab)is equivalent toL01FF04 (Avelumab)Reklassifizierung zu PD-1-/PD-L1-Inhibitoren
L01XC32 (Atezolizumab)is equivalent toL01FF05 (Atezolizumab)Reklassifizierung zu PD-1-/PD-L1-Inhibitoren
L01XC07 (Bevacizumab)is equivalent toL01FG01 (Bevacizumab)Reklassifizierung zu VEGF-/VEGFR-Inhibitoren
L01XC21 (Ramucirumab)is equivalent toL01FG02 (Ramucirumab)Reklassifizierung zu VEGF-/VEGFR-Inhibitoren
L01XC11 (Ipilimumab)is equivalent toL01FX04 (Ipilimumab)Reklassifizierung zu andere monoklonale Antikörper
L01XC12 (Brentuximab vedotin)is equivalent toL01FX05 (Brentuximab vedotin)Reklassifizierung zu andere monoklonale Antikörper
L01XC19 (Blinatumomab)is equivalent toL01FX07 (Blinatumomab)Reklassifizierung zu andere monoklonale Antikörper
L01XC27 (Olaratumab)is equivalent toL01FX10 (Olaratumab)Reklassifizierung zu andere monoklonale Antikörper
" }, "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability", "valueCode" : "shareable" }, { "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability", "valueCode" : "publishable" }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy", "valueCodeableConcept" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes", "code" : "package", "display" : "Package" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate", "valueDate" : "2026-09-15" }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic", "valueCodeableConcept" : { "coding" : [{ "system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code" : "C3262" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail" : { "telecom" : [{ "system" : "email", "value" : "thomas.debertshaeuser@charite.de" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor", "valueContactDetail" : { "name" : "Taskforce Core Data Set" } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer", "valueContactDetail" : { "name" : "Interoperability Working Group", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer", "valueContactDetail" : { "name" : "National Steering Committee", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser", "valueContactDetail" : { "name" : "Interoperability Working Group", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser", "valueContactDetail" : { "name" : "National Steering Committee", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm", "valueCoding" : { "system" : "http://hl7.org/fhir/version-algorithm", "code" : "semver", "display" : "SemVer" } }, { "url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod", "valuePeriod" : { "start" : "2027" } }], "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2022", "version" : "2027.0.0-ballot.1", "name" : "MII_CM_Onko_ATC_Transitions_2022", "title" : "MII CM Onko ATC Code Changes 2021 to 2022", "status" : "active", "experimental" : false, "date" : "2026-08-25", "publisher" : "Medizininformatik Initiative", "contact" : [{ "name" : "Medizininformatik Initiative", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/" }] }], "description" : "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2021 zu 2022. In diesem Jahr erfolgte die größte Reklassifikation der onkologischen ATC-Systematik: die monoklonalen Antikörper wurden aus der Sammelgruppe L01XC in die neue, nach Zielstruktur gegliederte Gruppe L01F überführt.", "jurisdiction" : [{ "coding" : [{ "system" : "urn:iso:std:iso:3166", "code" : "DE", "display" : "Germany" }] }], "purpose" : "Migration von ATC-Codes für monoklonale Antikörper, die 2022 von L01XC nach L01F umkodiert wurden.", "sourceCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021", "targetCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2022", "group" : [{ "source" : "http://fhir.de/CodeSystem/bfarm/atc", "target" : "http://fhir.de/CodeSystem/bfarm/atc", "element" : [{ "code" : "L01XC02", "display" : "Rituximab", "target" : [{ "code" : "L01FA01", "display" : "Rituximab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu CD20-Inhibitoren" }] }, { "code" : "L01XC15", "display" : "Obinutuzumab", "target" : [{ "code" : "L01FA03", "display" : "Obinutuzumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu CD20-Inhibitoren" }] }, { "code" : "L01XC26", "display" : "Inotuzumab ozogamicin", "target" : [{ "code" : "L01FB01", "display" : "Inotuzumab ozogamicin", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu CD22-Inhibitoren" }] }, { "code" : "L01XC24", "display" : "Daratumumab", "target" : [{ "code" : "L01FC01", "display" : "Daratumumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu CD38-Inhibitoren" }] }, { "code" : "L01XC03", "display" : "Trastuzumab", "target" : [{ "code" : "L01FD01", "display" : "Trastuzumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu HER2-Inhibitoren" }] }, { "code" : "L01XC13", "display" : "Pertuzumab", "target" : [{ "code" : "L01FD02", "display" : "Pertuzumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu HER2-Inhibitoren" }] }, { "code" : "L01XC14", "display" : "Trastuzumab emtansin", "target" : [{ "code" : "L01FD03", "display" : "Trastuzumab emtansin", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu HER2-Inhibitoren" }] }, { "code" : "L01XC06", "display" : "Cetuximab", "target" : [{ "code" : "L01FE01", "display" : "Cetuximab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu EGFR-Inhibitoren" }] }, { "code" : "L01XC08", "display" : "Panitumumab", "target" : [{ "code" : "L01FE02", "display" : "Panitumumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu EGFR-Inhibitoren" }] }, { "code" : "L01XC17", "display" : "Nivolumab", "target" : [{ "code" : "L01FF01", "display" : "Nivolumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren" }] }, { "code" : "L01XC18", "display" : "Pembrolizumab", "target" : [{ "code" : "L01FF02", "display" : "Pembrolizumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren" }] }, { "code" : "L01XC28", "display" : "Durvalumab", "target" : [{ "code" : "L01FF03", "display" : "Durvalumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren" }] }, { "code" : "L01XC31", "display" : "Avelumab", "target" : [{ "code" : "L01FF04", "display" : "Avelumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren" }] }, { "code" : "L01XC32", "display" : "Atezolizumab", "target" : [{ "code" : "L01FF05", "display" : "Atezolizumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren" }] }, { "code" : "L01XC07", "display" : "Bevacizumab", "target" : [{ "code" : "L01FG01", "display" : "Bevacizumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren" }] }, { "code" : "L01XC21", "display" : "Ramucirumab", "target" : [{ "code" : "L01FG02", "display" : "Ramucirumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren" }] }, { "code" : "L01XC11", "display" : "Ipilimumab", "target" : [{ "code" : "L01FX04", "display" : "Ipilimumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu andere monoklonale Antikörper" }] }, { "code" : "L01XC12", "display" : "Brentuximab vedotin", "target" : [{ "code" : "L01FX05", "display" : "Brentuximab vedotin", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu andere monoklonale Antikörper" }] }, { "code" : "L01XC19", "display" : "Blinatumomab", "target" : [{ "code" : "L01FX07", "display" : "Blinatumomab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu andere monoklonale Antikörper" }] }, { "code" : "L01XC27", "display" : "Olaratumab", "target" : [{ "code" : "L01FX10", "display" : "Olaratumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu andere monoklonale Antikörper" }] }] }] }